IFNG and non-small cell lung carcinoma: Then, one of the research groups carried out a phase II clinical trial to test the clinical benefit of IFN-γ-Dexs loaded with MHC class I- and class II-restricted cancer antigens that had been used in maintenance immunotherapy after induction chemotherapy in patients bearing inoperable non-small cell lung cancer (NSCLC) without tumor progression.